Amarin Corp Plc (AMRN)

[ggwpq]

Coleman's argument is, at this moment, FDA does not require CVOT results for LDL lowering therapy. Vascepa, in the eyes of FDA, is only a trig. lowering agent. Due to the failure of AIM-HIGH, THRIVE, etc., FDA requires Reduce-IT to be completed before ANCHOR approval. I think this is all BS. The bottom line is Amarin is a small bio with no connection. FDA is more than willing to bend over backward to facilitate BPs and those companies it has connections with(e.g. VNDA). Coleman and Mary Parks are without conscience. Imagine how many MACE would have been prevented in next four years if ANCHOR is approved now.